Antibiotic stories: a mixed-methods, multi-country analysis of household antibiotic use in Malawi, Uganda and Zimbabwe.
public health
qualitative study
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
23
07
2021
accepted:
12
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
As concerns about the prevalence of infections that are resistant to available antibiotics increase, attention has turned toward the use of these medicines both within and outside of formal healthcare settings. Much of what is known about use beyond formal settings is informed by survey-based research. Few studies to date have used comparative, mixed-methods approaches to render visible patterns of use within and between settings as well as wider points of context shaping these patterns. This article analyses findings from mixed-methods anthropological studies of antibiotic use in a range of rural and urban settings in Zimbabwe, Malawi and Uganda between 2018 and 2020. All used a 'drug bag' survey tool to capture the frequency and types of antibiotics used among 1811 households. We then undertook observations and interviews in residential settings, with health providers and key stakeholders to better understand the stories behind the most-used antibiotics. The most self-reported 'frequently used' antibiotics across settings were amoxicillin, cotrimoxazole and metronidazole. The stories behind their use varied between settings, reflecting differences in the configuration of health systems and antibiotic supplies. At the same time, these stories reveal cross-cutting features and omissions of contemporary global health programming that shape the contours of antibiotic (over)use at national and local levels. Our findings challenge the predominant focus of stewardship frameworks on the practices of antibiotic end users. We suggest future interventions could consider systems-rather than individuals-as stewards of antibiotics, reducing the need to rely on these medicines to fix other issues of inequity, productivity and security.
Sections du résumé
BACKGROUND
As concerns about the prevalence of infections that are resistant to available antibiotics increase, attention has turned toward the use of these medicines both within and outside of formal healthcare settings. Much of what is known about use beyond formal settings is informed by survey-based research. Few studies to date have used comparative, mixed-methods approaches to render visible patterns of use within and between settings as well as wider points of context shaping these patterns.
DESIGN
This article analyses findings from mixed-methods anthropological studies of antibiotic use in a range of rural and urban settings in Zimbabwe, Malawi and Uganda between 2018 and 2020. All used a 'drug bag' survey tool to capture the frequency and types of antibiotics used among 1811 households. We then undertook observations and interviews in residential settings, with health providers and key stakeholders to better understand the stories behind the most-used antibiotics.
RESULTS
The most self-reported 'frequently used' antibiotics across settings were amoxicillin, cotrimoxazole and metronidazole. The stories behind their use varied between settings, reflecting differences in the configuration of health systems and antibiotic supplies. At the same time, these stories reveal cross-cutting features and omissions of contemporary global health programming that shape the contours of antibiotic (over)use at national and local levels.
CONCLUSIONS
Our findings challenge the predominant focus of stewardship frameworks on the practices of antibiotic end users. We suggest future interventions could consider systems-rather than individuals-as stewards of antibiotics, reducing the need to rely on these medicines to fix other issues of inequity, productivity and security.
Identifiants
pubmed: 34836911
pii: bmjgh-2021-006920
doi: 10.1136/bmjgh-2021-006920
pmc: PMC8628329
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
ID : 206316/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S004793/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Trop Med Health. 2019 Jul 18;47:45
pubmed: 31360099
PLOS Glob Public Health. 2022 Jun 8;2(6):e0000314
pubmed: 36962375
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
Int J Infect Dis. 2021 Jul;108:473-482
pubmed: 34058373
BMC Health Serv Res. 2014 May 22;14:234
pubmed: 24884788
Palgrave Commun. 2019 May 22;5:
pubmed: 31157116
J Antimicrob Chemother. 2017 Feb;72(2):564-573
pubmed: 28115503
Lancet Infect Dis. 2020 Feb;20(2):179-187
pubmed: 31843383
JAC Antimicrob Resist. 2021 Oct 04;3(4):dlab150
pubmed: 34617017
J Antimicrob Chemother. 2019 Sep 1;74(9):2803-2809
pubmed: 31169902
Front Public Health. 2020 Apr 28;8:140
pubmed: 32411647
Wellcome Open Res. 2017 Jul 28;2:58
pubmed: 29707652
J Glob Antimicrob Resist. 2021 Jun;25:222-226
pubmed: 33845163
J Infect. 2019 Jan;78(1):8-18
pubmed: 29981773
Lancet Infect Dis. 2014 Aug;14(8):742-750
pubmed: 25022435
Lancet Infect Dis. 2019 Sep;19(9):930
pubmed: 31478515
PLoS One. 2018 Oct 31;13(10):e0206623
pubmed: 30379961
BMJ Glob Health. 2019 Aug 15;4(4):e001590
pubmed: 31497315
Lancet. 2018 Jan 6;391(10115):17-18
pubmed: 29323642
Lancet Infect Dis. 2011 Sep;11(9):692-701
pubmed: 21659004
Glob Health Action. 2019;12(1):1639388
pubmed: 31339473
Int J Antimicrob Agents. 2016 Jul;48(1):27-32
pubmed: 27318624
Health Res Policy Syst. 2020 Jun 8;18(1):60
pubmed: 32513200
Antimicrob Resist Infect Control. 2017 Nov 07;6:112
pubmed: 29152233
Clin Microbiol Infect. 2017 Nov;23(11):793-798
pubmed: 28882725
Int Health. 2010 Dec;2(4):262-8
pubmed: 24037867
Trop Med Int Health. 2012 Feb;17(2):211-22
pubmed: 21999394
BMJ Open. 2016 Mar 15;6(3):e010632
pubmed: 26980439
Malawi Med J. 2002 Sep;14(2):2-3
pubmed: 27528929
PLoS One. 2015 Jun 18;10(6):e0125439
pubmed: 26087147
Afr J Prim Health Care Fam Med. 2018 Jun 21;10(1):e1-e3
pubmed: 29943590
Lancet Infect Dis. 2019 Jan;19(1):67-75
pubmed: 30522834
Lancet Planet Health. 2018 Sep;2(9):e398-e405
pubmed: 30177008
BMJ Glob Health. 2018 Mar 28;3(2):e000621
pubmed: 29629190
BMJ Glob Health. 2020 Sep;5(9):
pubmed: 32967980
Lancet Glob Health. 2021 May;9(5):e610-e619
pubmed: 33713630
Soc Sci Med. 2021 Mar;272:113594
pubmed: 33529937
Lancet Glob Health. 2020 Jun;8(6):e799-e807
pubmed: 32446345
Bull World Health Organ. 2010 Dec 1;88(12):930-6
pubmed: 21124718
Soc Sci Med. 1994 Oct;39(8):1027-35
pubmed: 7809656
J Antimicrob Chemother. 2018 Apr 1;73(4):1112-1113
pubmed: 29361004